Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity

Wiesli, Peter; Bernays, René L.; Brändle, Michael; Zwimpfer, Cornelia; Seiler, Heidi; Zapf, J.; Spinas, Giatgen A.; Schmid, Christoph

doi:10.1016/j.cccn.2004.09.022

Cited by 20 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results support the view that adiponectin levels do not significantly improve during treatment of acromegaly. Contrasting to our findings, other authors did find a significant increase in adiponectin levels during acromegaly treatment, but the change was small (40,41).…”

Section: Discussioncontrasting

confidence: 99%

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly

Verhelst

Velkeniers²,

Maiter

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Patients with active acromegaly have an increased prevalence of cardiomyopathy and heart failure but a less than expected risk of coronary artery disease, considering the frequent association of diabetes mellitus and hypertension. We examined whether changes in high-sensitive C-reactive protein (hs-CRP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) might contribute to this phenomenon. Design and methods: Two hundred patients of the Belgian acromegaly registry (AcroBel) were divided in two groups: active disease (IGF1 Z-score O2; nZ95) and controlled disease (IGF1 Z-score %2; nZ105). Serum levels of hs-CRP and NT-proBNP were measured and correlated with BMI, blood pressure, fasting lipids, fasting glucose and insulin, HbA1c, IGF1, interleukin 6 (IL6), adiponectin, and sE-selectin. In a subset of acromegaly patients, hs-CRP, IL6, and NT-proBNP levels were also compared with those/the values of an age-, gender-, and BMI-matched reference group.

show abstract

Section: Discussioncontrasting

confidence: 99%

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly

Verhelst

Velkeniers²,

Maiter

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Interestingly, GH replacement therapy for several months in patients with GH deficiency did not change circulating adiponectin levels [5,6]. In contrast, circulating adiponectin levels increased several months after pituitary surgery in patients with acromegaly [7,8]. However, the relationship between circulating adiponectin and insulin sensitivity remains unclear since changes in body composition and insulin sensitivity may counteract each others effects in these studies with follow-up periods of several months.…”

Section: Introductionmentioning

confidence: 71%

Changes in insulin sensitivity induced by short-term growth hormone (GH) and insulin-like growth factor I (IGF-I) treatment in GH-deficient adults are not associated with changes in adiponectin levels

Schmid

Bianda

Zwimpfer

et al. 2005

Growth Hormone & IGF Research

Self Cite

View full text Add to dashboard Cite

“…172 In humans, however, there is presently a lack of consensus on whether elevated GH levels (such as in acromegaly) are associated with reduced adiponectin concentrations. [173][174][175][176] There is one positive report, however, of patients with acromegaly having low adiponectin levels that were reversed following GH-lowering therapy. 177 However, treatment of HIV-associated lipodystropy patients with recombinant human GH increased circulating adiponectin by approximately 20% and the increase of adiponectin was correlated with increases of HDL cholesterol.…”

Section: Endocrine Influences On Adiponectin Concentrationsmentioning

confidence: 91%

Physiological, Pharmacological, and Nutritional Regulation of Circulating Adiponectin Concentrations in Humans

Swarbrick

Havel

2008

Metabolic Syndrome and Related Disorders

219

176

View full text Add to dashboard Cite

Adiponectin is an adipocyte hormone that links visceral adiposity with insulin resistance and atherosclerosis. It is unique among adipocyte-derived hormones in that its circulating concentrations are inversely proportional to adiposity, and low adiponectin concentrations predict the development of type 2 diabetes and cardiovascular disease. Consequently, in the decade since its discovery, adiponectin has generated immense interest as a potential therapeutic target for the metabolic syndrome and diabetes. This review summarizes current research regarding the regulation of circulating adiponectin concentrations by physiological, pharmacological, and nutritional factors, with an emphasis on human studies. In humans, plasma adiponectin concentrations are influenced by age and gender, and are inversely proportional to visceral adiposity. In vitro studies suggest that adiponectin production may be determined primarily by adipocyte size and insulin sensitivity, with larger, insulin-resistant adipocytes producing less adiponectin. While adiponectin concentrations are unchanged after meal ingestion, they are increased by significant weight loss, such as after bariatric surgery. In addition, adiponectin production is inhibited by a number of hormones, including testosterone, prolactin, glucocorticoids and growth hormone, and by inflammation and oxidative stress in adipose tissue. Smoking decreases, while moderate alcohol consumption increases, circulating adiponectin concentrations. Dietary fatty acid composition in rodents influences adiponectin production via ligand-activated nuclear receptors (PPARs); however, current evidence in humans is equivocal. In addition to PPAR agonists (such as thiazolidinediones and fibrates), a number of pharmacological agents (angiotensin receptor type 1 blockers, ACE inhibitors, and cannabinoid receptor antagonists) used in treatment of the metabolic syndrome also increase adiponectin concentrations in humans.

show abstract

Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity

Cited by 20 publications

References 25 publications

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly

Changes in insulin sensitivity induced by short-term growth hormone (GH) and insulin-like growth factor I (IGF-I) treatment in GH-deficient adults are not associated with changes in adiponectin levels

Physiological, Pharmacological, and Nutritional Regulation of Circulating Adiponectin Concentrations in Humans

Contact Info

Product

Resources

About